Physician profile

Lee A Brock

Anesthesiology · Dallas, TX

NPI 1336126036

$4,506.55

in general payments reported to CMS, 2019-2025

44 companies · $661 in 2025

The $661 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).

See the full distribution for Anesthesiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,128.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $941.09 2019-2025 General - Pain Management, Wavewriter Alpha Prime 16
Abbott Laboratories $362.60 2019-2024 Proclaim
Abbvie INC. $352.29 2022-2025 Ubrelvy, Qulipta, Botox
Daiichi Sankyo INC. $324.76 2019
Collegium Pharmaceutical, INC. $309.11 2019-2025 Xtampza
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $263.94 2022-2025 Relistor
Medtronic, INC. $195.62 2022-2025 Intellis Adaptivestim, Inceptiv
Pacira Pharmaceuticals Incorporated $179.08 2023-2024 Exparel, Iovera, Zilretta
Pfizer INC. $146.52 2019-2024
Forte Bio-Pharma LLC $124.59 2020-2021
Curonix LLC $97.95 2024 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Protega Pharmaceutials INC $87.95 2025 Roxybond
Horizon Therapeutics Plc $86.59 2019-2022
Biohaven Pharmaceutical Holding Company LTD. $74.16 2022
Spinal Simplicity, LLC $73.21 2025 Ha Minuteman G3-R
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Nevro Corp. $69.94 2019-2023 Senza
Nalu Medical, INC. $58.84 2024-2025 Nalu Neurostimulation System
Scilex Pharmaceuticals INC. $51.77 2019-2021
Eisai INC. $51.04 2020-2021
Sentynl Therapeutics, INC. $43.99 2019
Painteq LLC $41.22 2024 Painteq
Almatica Pharma LLC $40.64 2021-2022
Uswm, LLC $38.98 2023 Lucemyra, Zimhi
Spr Therapeutics, INC $38.53 2024-2025 Sprint Pns System
Globus Medical, INC. $36.62 2025 Senza
Arbor Pharmaceuticals, INC. $36.22 2019-2020
Vertiflex, INC. $35.34 2019
Azurity Pharmaceuticals, INC. $32.74 2023-2025 Horizant, Horizant
Saluda Medical Americas, INC. $31.05 2025 Evoke
Novartis Pharmaceuticals Corporation $30.34 2020
Si-Bone, INC. $29.48 2023
Takeda Pharmaceuticals U.S.A., INC. $23.84 2019-2020
Assertio Therapeutics, INC. $23.03 2019
Bioventus LLC $21.13 2023 Durolane
Valinor Pharma, LLC $19.16 2025 Movantik
Foundation Fusion Solutions, LLC $17.89 2024
Medtronic USA, INC. $16.71 2020
Mdd US Operations, LLC $16.24 2020
Redhill Biopharma INC. $16.03 2020
Pernix Therapeutics Holdings, INC. $14.23 2019
Cpm Medical Consultants, LLC $13.81 2019
Teva Pharmaceuticals USA, INC. $13.32 2019
Biodelivery Sciences International, INC. $13.11 2019
Avanos Medical $11.85 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lee A Brock

$4,506.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $661 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).

https://glasscript.com/doctor/332922/lee-a-brock

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.